Research

Oxford University research has contributed to strategies to eliminate malaria in the Greater Mekong Sub-region, helping to prevent the spread of drug-resistant malaria and improving health provision and outcomes for remote communities.

Researchers at the University of Oxford have made the case for sugar taxes to reduce obesity and boost health – influencing policy in Mexico, Ireland, and the UK.

Dr Kira Allmann and colleagues have worked with public libraries across Oxfordshire to identify barriers to digital inclusion and develop recommendations to help libraries better support digital access and skill development.

Research at the University of Oxford has validated and extended a novel approach to preventing depression.

Marenka-Thompson-Odlum and colleagues examined the Pitt Rivers’ Collection Development Policy in the light of initiatives to decolonise the museum, gaining insights and recommendations which will inform a policy update.

Ithaca is the first deep neural network that can aid historians in not only restoring the missing text of damaged inscriptions, but also identifying their original location, and establishing the date they were written.

Maryam Ahmadyar worked with St Basils charity, Birmingham, to explore the barriers faced by young homeless people in accessing dental care, and develop recommendations to improve services.

Professor David Howey and colleagues in the Department of Engineering Science are using big data to improve battery testing – a vital step towards a clean energy future.

Projects funded by this round of the scheme will support new research into a wide range of topics from the function of music in the acquisition of knowledge to the Communist Movement in Burma and the study of Syro-Armenian polemics in the eleventh and twelfth centuries.

A new approach to point-of-care testing is offering patients with serious mental health conditions vital health checks at routine appointments – boosting their health chances and saving time and money for the NHS

The researchers believe their work could enable Oxford’s ChAdOx vaccines to hit the “moonshot” objective set earlier this year by the Coalition for Epidemic Preparedness Innovations (CEPI), which aims to help compress vaccine development timelines to 100 days from pathogen identification to mass

Researchers from the University of Oxford have analysed the impact of the Omicron COVID-19 variant of concern on one of the immune responses generated by vaccination.

Featuring notable speakers from across the fields of  business, science or politics  almost every year since 1972, Prof.

Professors Dame Sarah Gilbert, Teresa Lambe, Sir Andrew Pollard and Fiona Powrie received the awards for contributions to the field of immunology, from developing the ChAdOx1 nCoV-19 coronavirus vaccine to pioneering gut immunology research and have inspired scores of new immunologists in the fie

University researchers reveal invention of simple manufacturing method which has enabled rapid scale up of vaccine manufacturing in 15 countries around the world, reaching people across seven continentsApproach provides a template for faster and more equitable supply of other vaccin

New algorithm predicts those most at risk of serious Covid-19 outcomes from 14 or more days after second vaccination dose, when substantial immunity is expected to have developedAuthors hope this new risk tool will allow those who perceive risk to be high to make more informed decis

The accolade is one of a selection of prizes and medals awarded today by the British Academy, the national body for the humanities and social sciences, for notable contributions to fields including Linguistics, Cultural History and Biblical Studies and is shared with Gillian Russell, Professor of

Study compares risks of thrombocytopenia and thromboembolic events following ChAdOx1 nCov-19 (Oxford-AstraZeneca), BNT162b2 mRNA (Pfizer-BioNTech) vaccination, and SARS-CoV-2 (Covid-19) infectionStudy shows increased risk of thrombocytopenia and venous thromboembolism wi

AstraZeneca, with their extensive world-wide development and manufacturing capabilities, have been able to have the vaccine approved and licenced for use in over 170 countries, with over 20 manufacturing sites across the world, including the Serum Institute of India, working together to release t

The trial, funded by Innovate UK, part of UK Research and Innovation https://www.ukri.org/, uses a vaccine based on the ChAdOx1 adenovirus viral vector platform al